Work

Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2037

Authors: Michael J Ciesielski, Manmeet Singh Ahluwalia, David A. Reardon, Ajay P. Abad, William T. Curry, Eric T. Wong, David M. Peereboom, Sheila A. Figel, Alan Hutson, Adrienne Groman, Henry G. Withers, Song Liu, Ahmed Belal, Jing-Xin Qiu, Kathleen Mogensen, Cathy Schilero, Danielle M. Casucci, Laszlo Mechtler, Robert Alan Fenstermaker

Institutions: Roswell Park Comprehensive Cancer Center, Cleveland Clinic, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dent Neurologic Institute

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286296038

Cites:

Cited by: 7

Related to: 10